All In Biotech

Drug Trial Radar · NCT07108283

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

207

Actual

Start

Nov 3, 2025

Primary completion

Mar 26, 2027

Study completion Nov 9, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.

Conditions

  • Nonsegmental Vitiligo

Interventions

  • ZasocitinibDrug

    Zasocitinib capsules.

  • PlaceboOther

    Zasocitinib matching placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving >= 75% Improvement From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24Time frame: Baseline, Week 24

Locations

67 sites in 9 countries. Site status is shown where the registry gives one.

  • Dermatology Trial Associates

    Bryant, Arkansas

  • First OC Dermatology

    Fountain Valley, California

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California

  • The Vitiligo & Pigmentation Institute of Southern California

    Los Angeles, California

  • UC Davis Department of Dermatology

    Sacramento, California

  • Therapeutics Clinical Research

    San Diego, California

  • Encore Medical Research of Boynton Beach LLC.

    Boynton Beach, Florida

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • Advanced Clinical Research Institute (ACRI)

    Tampa, Florida

  • Encore Medical Research of Weston LLC

    Weston, Florida

  • DelRicht Research - Dermatology

    Baton Rouge, Louisiana

  • DelRicht Research (Audubon Dermatology)

    New Orleans, Louisiana

  • Lawrence J Green LLC

    Rockville, Maryland

  • Hamzavi Dermatology - Canton

    Canton, Michigan

  • Weill Cornell Medicine

    New York, New York

  • Markowitz Medical dba Optiskin

    New York, New York

  • Medical University of South Carolina

    Charleston, South Carolina

  • UT Health Science Center Houston

    Bellaire, Texas

  • ACRC Trials

    Plano, Texas

  • Progressive Clinical Research-San Antonio

    San Antonio, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Brunswick Dermatology Center (BDC)

    Fredericton, New Brunswick, Canada

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, Canada

  • LEADER research

    Hamilton, Ontario, Canada

  • The Centre for Clinical Trials

    Oakville, Ontario, Canada

  • SKiN Centre for Dermatology

    Peterborough, Ontario, Canada

  • North York Research Inc

    Toronto, Ontario, Canada

  • Centre de Recherche Dermatologique de Quebec

    Québec, Quebec, Canada

  • Skinsense Medical Research

    Saskatoon, Saskatchewan, Canada

  • The First Hospital of Wuhan

    Wuhan, Hubei, China

  • First Affiliated Hospital of Xi 'an Jiaotong University

    Xi'an, Shaanxi, China

  • Huashan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Kunming Medical College

    Kunming, Yunnan, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • Bordeaux University Hospital

    Bordeaux, France

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Henri Mondor (Hopital Henri-Mondor)

    Créteil, France

  • Centre Hospitalier Le Mans (CHM)

    Le Mans, France

  • Cabinet Medical du Dr Ruer

    Martigues, France

  • Centre Hospitalier Universitaire de Nice - Hopital l'Archet

    Nice, France

  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Larrey

    Toulouse, France

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.